Search the Newsreel

Abbott Laboratories stock underperforms Tuesday when compared to competitors

Abbott Laboratories (ABT) stock declined by 1.55% on Tuesday, closing at $105.46. This underperformance occurred on a day when the broader market, including the S&P 500 and Dow Jones Industrial Average, saw significant gains. The stock's fall ended a two-day winning streak for Abbott …

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share …

AbbVie (ABBV) Lifted Guidance, Has The Market Already Priced It In?

AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal

AbbVie Inc. is reportedly looking to raise at least $8 billion, and potentially up to $10 billion, through an investment-grade bond offering. The pharmaceutical giant intends to use these funds to finance a portion of its acquisition of Apogee Therapeutics Inc. The final size …

Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating

Guggenheim has increased its price target for AbbVie (NYSE: ABBV) to $288 from $261, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with Rothschild & Co Redburn also adjusting its target to $285 and Oppenheimer …

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

If approved, BOTOX®Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle …

UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

UBRELVY®(ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC)is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies. CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults. Migraine affects an estimated 5 million Canadians with the …

ABB India Standalone June 2026 Net Sales at Rs 3,558.87 crore, up 12.07% Y-o-Y

Abbott Laboratories Stock (ABT) Opinions on Q2 Earnings Beat and Guidance Raise

Why You Might Be Interested In ABB India Limited (NSE:ABB) For Its Upcoming Dividend

AbbVie’s Growth Now Leans On A Single Molecule

AbbVie's future growth is heavily reliant on a single drug, SKYRIZI, which is projected to account for close to one-third of the company's total revenue in 2026. While the patent for SKYRIZI extends well into the 2030s, the company faces a challenge with its …

Abbott Laboratories stock rises Monday, still underperforms market

Abbott Laboratories (ABT) stock increased by 1.34% to $107.12 on Monday, marking its second consecutive day of gains. Despite this rise, the stock underperformed the broader market, as the S&P 500 Index rose by 1.48% and the Dow Jones Industrial Average gained 1.32% on …

AbbVie Inc. stock underperforms Monday when compared to competitors

AbbVie Inc. (ABBV) stock fell 2.33% on Monday, closing at $245.10, despite a generally positive trading session where the S&P 500 and Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for AbbVie, underperforming its competitors. The article …

Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant

Abbott Laboratories has seen its stock decline by 16% this year, despite five consecutive adjusted EPS beats, primarily due to the financial impact of its $21 billion Exact Sciences acquisition. While the market reacted negatively to GAAP earnings, analysts like Barclays' Matt Miksic see …

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

AbbVie (ABBV) reported another "strong" quarter operationally, with investor attention increasingly PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary

AbbVie Inc. reported its 2026 quarterly results, with revenue reaching $16.99 billion and diluted EPS at $2.03, marking significant growth over the prior year. This performance was attributed to strong sales of key brands like Skyrizi, Rinvoq, and neuroscience products, despite a decline in …

Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight

DelveInsight Business Research LLP The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering …

Matrix Asset Advisors' Large Cap Value Portfolio adds ABT and MCD; exits NSRGY

* Matrix Asset Advisors' Large Cap Value Portfolio gained in the mid-teens in Q2 2026, roughly in line with the S&P 500, which returned 15.2% and modestly ahead of the Russell 1000 Value Index. * The firm initiated new positions in Abbott Laboratories (NYSE: …

Canaccord raises Abbvie stock price target to $290 on Q2 beat

Canaccord Genuity increased its price target for Abbvie Inc. (NYSE:ABBV) to $290 from $282, maintaining a Buy rating, following the company's strong second-quarter performance. Abbvie exceeded revenue and earnings expectations, particularly in its Immunology and Neuroscience franchises, leading to a raised 2026 revenue guidance. …

Abbisko Sets August Board Meeting to Approve Interim Results and Weigh Dividend

AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter

Morningstar is maintaining its $200 fair value estimate for wide-moat AbbVie following a strong second quarter, which saw 10.2% top-line growth and 22.9% adjusted diluted EPS growth. The company's immunology portfolio, particularly Skyrizi and Rinvoq, continues to drive strong double-digit growth, despite increasing competition. …

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Inc. ABBV paired strong product momentum with a more complex 2026 outlook. Management raised revenue expectations, while the planned Apogee Therapeutics acquisition pushed adjusted earnings guidance modestly lower. The call focused on Skyrizi, Rinvoq and neuroscience growth, the case for Apogee and a …

Abbott Laboratories (ABT) Stock Analysis: Navigating a 12% Upside Potential Amid Robust Healthcare Offerings

ABB India Shares Gain 2.09% in Early Trade

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Abbott Laboratories (NYSE:ABT) and Eli Lilly (NYSE:LLY) involves weighing the steady diversification of a healthcare conglomerate against the high-velocity expansion of a pharmaceutical leader. Both companies represent different investment profiles. Abbott operates as a diversified healthcare giant with interests ranging from infant …

Abbott (ABT) Stock Looks Like A Bargain Below Fair Value

Abbott Laboratories' stock has dropped 15% over the past year, and a Discounted Cash Flow (DCF) analysis suggests it is undervalued by 28.9%, with an intrinsic value of about $149 per share. However, its P/E ratio of 33.9x is higher than the industry average, …

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie (ABBV) has successfully diversified its business beyond its previous dependence on Humira, with strong Q2 revenue and earnings growth driven by its Immunology and Neurosciences segments. Analysts maintain a "Moderate Buy" rating, anticipating the stock could reach $300 within 12 months, despite a …

AbbVie (ABBV) Stock Faces A Pivotal Growth Handoff After Guidance Lift

AbbVie Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, AbbVie (ABBV) has approximately 57,960 total employees worldwide, a growth of 11.0% since 2023. The company is actively hiring, with 2,862 job postings in 2026, and its workforce is concentrated in the United States, followed by India and Ireland. The …

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.

AbbVie (ABBV) Stock Could Sit Below Fair Value While Earnings Look Rich

Why AbbVie Stock Slumped Today

AbbVie's stock fell by nearly 3% after its second-quarter earnings report, despite strong revenue growth, because its adjusted profitability of $3.65 per share missed analyst estimates of $3.71. Additionally, the company slightly cut its 2026 profitability outlook due to its acquisition of Apogee Therapeutics, …

AbbVie's Skyrizi and Rinvoq Launches Support Lengthy Patent Protection and a Wide Moat

AbbVie's key drugs Skyrizi and Rinvoq are providing strong support for the company's lengthy patent protection and wide economic moat. Despite biosimilar competition impacting Humira revenue in 2023, AbbVie returned to growth in 2024, demonstrating the resilience of its diversified portfolio. The company maintains …

AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

AbbVie (ABBV) has received European Commission approval for its drug RINVOQ (upadacitinib) for new indications in the EU. RINVOQ is now approved as the first systemic treatment for non-segmental vitiligo and as a systemic option for severe alopecia areata in adults and adolescents. These …

AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ...

This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (NYSE:ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, …

AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading